{"ATC Code":"C01CA02","Abbreviation":"","Aliases":["isoproterenol","Isopropydrin","Asiprenol","Assiprenol","Bellasthman","Isoprenalin","Respifral","Aludrine","Asmalar","Neodrenal"],"Biological Half-Life":"The half life of intravenous isoprenaline is 2.5-5 minutes. Oral isoprenaline has a half life of 40 minutes.","CAS":"7683-59-2","ChEBI":"CHEBI:64317","ChEMBL":"CHEMBL434","ChemicalClasses":["phenylethanolamine","catecholamine"],"Chirality":"racemic","Classes":["Sympathomimetic"],"Dosing Info":[],"Drug Indication":"Isoprenaline is indicated to treat mild or transient episodes of heart block not requiring electric shock or pacemakers, serious episodes of heart block and Adams-Stokes attacks not caused by ventricular tachycardia or fibrillation, and bronchospasm during anesthesia. Isoprenaline is also indicated for cases of cardiac arrest until preferable treatments like electric shock and pacemakers are available. Isoprenaline is also indicated as an adjunct therapy to fluid and electrolyte replacement therapy in hypovolemic shock, septic shock, hypoperfusion, congestive heart failure, and cardiogenic shock.","DrugClasses":[],"DurationOfAction":"Inhalation: 0.5–2\u0026nbsphours","EINECS":"231-687-7","EliminationHalfLife":"Intravenous infusion: 2.5–5\u0026nbspmin Oral: 40\u0026nbspmin","European Community (EC) Number":"231-687-7","FDA Pharmacological Classification":"L628TT009W","FullSalts":["Isoprenaline hydrochloride","Isoprenaline sulfate"],"HMDB ID":"HMDB0015197","HeavyAtomCount":15,"Human Drugs":"Human drug -\u003e Discontinued","IUPACName":"4-[1-hydroxy-2-(propan-2-ylamino)ethyl]benzene-1,2-diol","InChI":"InChI=1S/C11H17NO3/c1-7(2)12-6-11(15)8-3-4-9(13)10(14)5-8/h3-5,7,11-15H,6H2,1-2H3","InChIKey":"JWZZKOKVBUJMES-UHFFFAOYSA-N","MeSH Pharmacological Classification":"Drugs that mimic the effects of stimulating postganglionic adrenergic sympathetic nerves. Included here are drugs that directly stimulate adrenergic receptors and drugs that act indirectly by provoking the release of adrenergic transmitters. (See all compounds classified as Sympathomimetics.)","Melting Point":"170.5 °C","MolecularFormula":"C\u003csub\u003e11\u003c/sub\u003eH\u003csub\u003e17\u003c/sub\u003eNO\u003csub\u003e3\u003c/sub\u003e","MolecularWeight":"211.26 g/mol","Opticalactivity":"( + / - )","Pharmacodynamics":"Isoprenaline is a non-selective beta adrenergic receptor agonist used in a number of indications for the heart, as well as bronchospasm in anesthesia. Isoprenaline has a short duration of action as it is rapidly cleared, and a wide therapeutic index. Patients should be counselled regarding the risks of isoprenaline in the treatment of cardiogenic shock following myocardial infarction, paradoxical worsening of heart block, or precipitation of Adams-Stokes attacks.","Physical Description":"Solid","PrevSalts":["hydrochloride","sulfate"],"PubChemId":3779,"Record Description":["Isoprenaline is a secondary amino compound that is noradrenaline in which one of the hydrogens attached to the nitrogen is replaced by an isopropyl group. A sympathomimetic acting almost exclusively on beta-adrenergic receptors, it is used (mainly as the hydrochloride salt) as a bronghodilator and heart stimulant for the management of a variety of cardiac disorders. It has a role as a sympathomimetic agent, a beta-adrenergic agonist, a bronchodilator agent and a cardiotonic drug. It is a member of catechols, a secondary amino compound and a secondary alcohol.","Isoprenaline is a non-selective beta adrenergic receptor agonist indicated to treat heart block, Adams-Stokes attacks, bronchospasm in anesthesia, cadiac arrest, hypovolemic shocks, septic shock, hypoperfusion, congestive hear failure, and cardiogenic shock.  Isoprenaline research in the 1940s found that this isopropyl analog of epinephrine dilated the bronchi, as well as raising the heart rate and cardiac output, without vasoconstriction. The US patent from 1943 states that this compound had a wider therapeutic index and a stronger action than [adrenaline].  Isoprenaline was granted FDA approval on 19 February 1948.","Isoproterenol is a beta-Adrenergic Agonist. The mechanism of action of isoproterenol is as an Adrenergic beta-Agonist.","Isoproterenol is a synthetic catechol compound and potent beta adrenergic agonist with peripheral vasodilator, bronchodilator, and cardiac stimulating properties. Isoproterenol exerts its effect on the beta-1 adrenergic receptors in the myocardium, thereby increasing heart rate and cardiac output. In addition, isoproterenol acts on beta-2 adrenergic receptors in bronchiolar and vascular smooth muscle, thereby causing smooth muscle relaxation.","ISOPROTERENOL is a small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1956 and has 3 approved and 6 investigational indications.","Isopropyl analog of epinephrine; beta-sympathomimetic that acts on the heart, bronchi, skeletal muscle, alimentary tract, etc. It is used mainly as bronchodilator and heart stimulant. [PubChem]","Isopropyl analog of EPINEPHRINE; beta-sympathomimetic that acts on the heart, bronchi, skeletal muscle, alimentary tract, etc. It is used mainly as bronchodilator and heart stimulant.","See also: Isoproterenol Hydrochloride (has salt form); Isoproterenol Sulfate (has salt form).","Isoprenaline is a secondary amino compound that is noradrenaline in which one of the hydrogens attached to the nitrogen is replaced by an isopropyl group. A sympathomimetic acting almost exclusively on beta-adrenergic receptors, it is used (mainly as the hydrochloride salt) as a bronghodilator and heart stimulant for the management of a variety of cardiac disorders. It has a role as a sympathomimetic agent, a beta-adrenergic agonist, a bronchodilator agent and a cardiotonic drug. It is a member of catechols, a secondary amino compound and a secondary alcohol."],"References":[{"Name":"Wikipedia","Urls":[{"Link":"https://en.wikipedia.org/wiki/Isoprenaline","Name":"Isoprenaline","Sub":false},{"Link":"https://en.wikipedia.org/wiki/Levisoprenaline","Name":"(-)-Isoprenaline","Sub":true}]},{"Name":"Wikidata","Urls":[{"Link":"https://www.wikidata.org/wiki/Q415550","Name":"Isoprenaline","Sub":false},{"Link":"https://www.wikidata.org/wiki/Q27166424","Name":"(+)-Isoprenaline","Sub":true},{"Link":"https://www.wikidata.org/wiki/Q26841340","Name":"(-)-Isoprenaline","Sub":true}]},{"Name":"DrugBank","Urls":[{"Link":"https://go.drugbank.com/drugs/DB01064","Name":"Isoprenaline","Sub":false}]},{"Name":"PubChem","Urls":[{"Link":"https://pubchem.ncbi.nlm.nih.gov/compound/3779","Name":"Isoprenaline","Sub":false},{"Link":"https://pubchem.ncbi.nlm.nih.gov/compound/5808","Name":"(+)-Isoprenaline","Sub":true},{"Link":"https://pubchem.ncbi.nlm.nih.gov/compound/443372","Name":"(-)-Isoprenaline","Sub":true}]},{"Name":"ChEMBL","Urls":[{"Link":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL434","Name":"Isoprenaline","Sub":false},{"Link":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL460574","Name":"(+)-Isoprenaline","Sub":true},{"Link":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL1160723","Name":"(-)-Isoprenaline","Sub":true}]},{"Name":"ChEBI","Urls":[{"Link":"https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:64317","Name":"Isoprenaline","Sub":false},{"Link":"https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:94595","Name":"(+)-Isoprenaline","Sub":true},{"Link":"https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:6257","Name":"(-)-Isoprenaline","Sub":true}]},{"Name":"Common Chemistry","Urls":[{"Link":"https://commonchemistry.cas.org/detail?cas_rn=7683-59-2","Name":"Isoprenaline","Sub":false},{"Link":"https://commonchemistry.cas.org/detail?cas_rn=2964-04-7","Name":"(+)-Isoprenaline","Sub":true},{"Link":"https://commonchemistry.cas.org/detail?cas_rn=51-31-0","Name":"(-)-Isoprenaline","Sub":true}]},{"Name":"HMDB","Urls":[{"Link":"https://hmdb.ca/metabolites/HMDB0015197","Name":"Isoprenaline","Sub":false}]},{"Name":"KEGG","Urls":[{"Link":"https://www.kegg.jp/entry/C07056","Name":"Isoprenaline","Sub":false},{"Link":"https://www.kegg.jp/entry/C11703","Name":"(-)-Isoprenaline","Sub":true}]},{"Name":"UNII","Urls":[{"Link":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/L628TT009W","Name":"Isoprenaline","Sub":false},{"Link":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/70D2X5QMKK","Name":"(+)-Isoprenaline","Sub":true},{"Link":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/588N0603CT","Name":"(-)-Isoprenaline","Sub":true}]},{"Name":"EPA DSSTox","Urls":[{"Link":"https://comptox.epa.gov/dashboard/chemical/details/DTXSID4023175","Name":"Isoprenaline","Sub":false},{"Link":"https://comptox.epa.gov/dashboard/chemical/details/DTXSID2043878","Name":"(-)-Isoprenaline","Sub":true}]}],"SMILES":"CC(C)NCC(C1=CC(=C(C=C1)O)O)O","Salts":["hydrochloride","sulfate"],"SaltsAcidCount":[1,1],"SaltsAmineCount":[1,2],"SaltsUNII":["DIA2A74855","925FX3X776"],"Scheduling":[{"gov":"Australia","schedule":"S4 substance"}],"Solubility":"5.86e+00 g/L","StereoisomerRacemic":"(RS)-Isoprenaline","Stereoisomers":["(+)-Isoprenaline","(-)-Isoprenaline"],"StereoisomersUNII":["70D2X5QMKK","588N0603CT"],"StoreUNII":["L628TT009W"],"StructureBase64":"<svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" height="51.882mm" version="1.2" viewBox="0 0 113.755 51.882" width="113.755mm">
      
    <desc>Generated by the Chemistry Development Kit (http://github.com/cdk)</desc>
      
    <g fill="#FF0D0D" stroke="#000000" stroke-linecap="round" stroke-linejoin="round" stroke-width=".7">
            
        <rect fill="#FFFFFF" height="52.0" stroke="none" width="114.0" x=".0" y=".0"/>
            
        <g class="mol" id="mol1">
                  
            <line class="bond" id="mol1bnd1" x1="112.717" x2="99.519" y1="18.321" y2="25.941"/>
                  
            <line class="bond" id="mol1bnd2" x1="99.519" x2="99.519" y1="25.941" y2="41.181"/>
                  
            <line class="bond" id="mol1bnd3" x1="99.519" x2="89.474" y1="25.941" y2="20.142"/>
                  
            <line class="bond" id="mol1bnd4" x1="83.168" x2="73.123" y1="20.142" y2="25.941"/>
                  
            <line class="bond" id="mol1bnd5" x1="73.123" x2="59.924" y1="25.941" y2="18.321"/>
                  
            <line class="bond" id="mol1bnd6" x1="59.924" x2="46.726" y1="18.321" y2="25.941"/>
                  
            <g class="bond" id="mol1bnd7">
                        
                <line x1="46.726" x2="33.523" y1="25.941" y2="18.313"/>
                        
                <line x1="44.288" x2="33.523" y1="27.349" y2="21.129"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd8" x1="33.523" x2="20.325" y1="18.313" y2="25.933"/>
                  
            <g class="bond" id="mol1bnd9">
                        
                <line x1="20.325" x2="20.33" y1="25.933" y2="41.181"/>
                        
                <line x1="22.764" x2="22.768" y1="27.34" y2="39.774"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd10" x1="20.33" x2="33.533" y1="41.181" y2="48.81"/>
                  
            <g class="bond" id="mol1bnd11">
                        
                <line x1="33.533" x2="46.731" y1="48.81" y2="41.19"/>
                        
                <line x1="33.533" x2="44.292" y1="45.994" y2="39.782"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd12" x1="46.726" x2="46.731" y1="25.941" y2="41.19"/>
                  
            <line class="bond" id="mol1bnd13" x1="20.33" x2="10.41" y1="41.181" y2="46.908"/>
                  
            <line class="bond" id="mol1bnd14" x1="20.325" x2="10.401" y1="25.933" y2="20.205"/>
                  
            <line class="bond" id="mol1bnd15" x1="59.924" x2="59.924" y1="18.321" y2="7.002"/>
                  
            <g class="atom" id="mol1atm4">
                        
                <path d="M88.262 20.771h-.721l-2.619 -4.066h-.03q.012 .238 .03 .595q.024 .357 .024 .732v2.739h-.566v-4.9h.715l2.607 4.055h.03q-.006 -.108 -.018 -.328q-.012 -.22 -.024 -.476q-.006 -.262 -.006 -.482v-2.769h.578v4.9z" fill="#3050F8" stroke="none"/>
                        
                <path d="M88.125 15.31h-.619v-2.286h-2.513v2.286h-.613v-4.9h.613v2.072h2.513v-2.072h.619v4.9z" fill="#3050F8" stroke="none"/>
                      
            </g>
                  
            <g class="atom" id="mol1atm13">
                        
                <path d="M9.391 48.798q-.0 .756 -.256 1.328q-.256 .565 -.756 .881q-.5 .315 -1.245 .315q-.756 .0 -1.262 -.315q-.506 -.316 -.756 -.887q-.244 -.572 -.244 -1.334q.0 -.75 .244 -1.309q.25 -.566 .756 -.881q.506 -.316 1.274 -.316q.733 .0 1.233 .316q.5 .309 .756 .875q.256 .565 .256 1.327zM5.527 48.798q.0 .923 .387 1.459q.393 .53 1.22 .53q.84 -.0 1.221 -.53q.387 -.536 .387 -1.459q-.0 -.929 -.387 -1.452q-.381 -.524 -1.209 -.524q-.833 -.0 -1.226 .524q-.393 .523 -.393 1.452z" stroke="none"/>
                        
                <path d="M4.311 51.251h-.62v-2.286h-2.512v2.286h-.613v-4.9h.613v2.072h2.512v-2.072h.62v4.9z" stroke="none"/>
                      
            </g>
                  
            <g class="atom" id="mol1atm14">
                        
                <path d="M9.385 18.312q-.0 .756 -.256 1.327q-.256 .566 -.756 .881q-.5 .316 -1.245 .316q-.756 -.0 -1.262 -.316q-.506 -.315 -.756 -.887q-.244 -.571 -.244 -1.333q.0 -.75 .244 -1.31q.25 -.565 .756 -.881q.506 -.315 1.274 -.315q.733 -.0 1.233 .315q.5 .31 .756 .875q.256 .566 .256 1.328zM5.521 18.312q.0 .923 .387 1.458q.393 .53 1.22 .53q.84 .0 1.221 -.53q.387 -.535 .387 -1.458q-.0 -.929 -.387 -1.453q-.381 -.524 -1.209 -.524q-.833 .0 -1.226 .524q-.393 .524 -.393 1.453z" stroke="none"/>
                        
                <path d="M4.305 20.765h-.62v-2.286h-2.512v2.286h-.613v-4.9h.613v2.072h2.512v-2.072h.62v4.9z" stroke="none"/>
                      
            </g>
                  
            <g class="atom" id="mol1atm15">
                        
                <path d="M62.184 3.078q-.0 .756 -.256 1.328q-.256 .565 -.756 .881q-.5 .315 -1.245 .315q-.756 .0 -1.262 -.315q-.506 -.316 -.756 -.887q-.244 -.572 -.244 -1.334q.0 -.75 .244 -1.309q.25 -.566 .756 -.881q.506 -.316 1.274 -.316q.733 .0 1.233 .316q.5 .309 .756 .875q.256 .565 .256 1.327zM58.32 3.078q.0 .923 .387 1.459q.393 .53 1.22 .53q.84 -.0 1.221 -.53q.387 -.536 .387 -1.459q-.0 -.929 -.387 -1.452q-.381 -.524 -1.209 -.524q-.833 -.0 -1.226 .524q-.393 .523 -.393 1.452z" stroke="none"/>
                        
                <path d="M66.49 5.531h-.619v-2.286h-2.513v2.286h-.613v-4.9h.613v2.072h2.513v-2.072h.619v4.9z" stroke="none"/>
                      
            </g>
                
            <line class="hi" id="mol1bnd3" stroke="#3050F8" x1="89.474" x2="94.4965" y1="20.142" y2="23.0415"/>
            <line class="hi" id="mol1bnd3" stroke="#3050F8" x1="89.474" x2="94.4965" y1="20.142" y2="23.0415"/>
            <line class="hi" id="mol1bnd4" stroke="#3050F8" x1="83.168" x2="78.1455" y1="20.142" y2="23.0415"/>
            <line class="hi" id="mol1bnd4" stroke="#3050F8" x1="83.168" x2="78.1455" y1="20.142" y2="23.0415"/>
            <line class="hi" id="mol1bnd13" stroke="#FF0D0D" x1="10.41" x2="15.37" y1="46.908" y2="44.0445"/>
            <line class="hi" id="mol1bnd13" stroke="#FF0D0D" x1="10.41" x2="15.37" y1="46.908" y2="44.0445"/>
            <line class="hi" id="mol1bnd14" stroke="#FF0D0D" x1="10.401" x2="15.363" y1="20.205" y2="23.069"/>
            <line class="hi" id="mol1bnd14" stroke="#FF0D0D" x1="10.401" x2="15.363" y1="20.205" y2="23.069"/>
            <line class="hi" id="mol1bnd15" stroke="#FF0D0D" x1="59.924" x2="59.924" y1="7.001999999999999" y2="12.6615"/>
            <line class="hi" id="mol1bnd15" stroke="#FF0D0D" x1="59.924" x2="59.924" y1="7.001999999999999" y2="12.6615"/>
        </g>
          
    </g>
    
</svg>
","Title":"Isoprenaline","UNII":"L628TT009W","Wikidata":"Q415550","Wikipedia":"Isoprenaline","XLogP":-0.6}